The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Open accessAbstract
PURPOSE: Patients with acute myeloid leukemia (AML) in remission remain at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) status before alloHCT has been shown to be prognostic. Whether modulation of the intensity of the alloHCT conditioning regimen in patients with AML who test positive for MRD can prevent relapse and improve survival is unknown. METHODS: Ultra-deep, error-corrected sequencing for 13 commonly mutated genes in AML was performed on preconditioning blood from patients treated in a phase III clinical trial that randomly assigned adult patients with myeloid malignancy in morphologic complete remission to myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC). RESULTS: No mutations were detected in 32% of MAC and 37% of RIC recipients; these groups had similar survival (3-year overall survival [OS], 56% v 63%; P = .96). In patients with a detectable mutation (next-generation sequencing [NGS] positive), relapse (3-year cumulative incidence, 19% v 67%; P < .001) and survival (3-year OS, 61% v 43%; P = .02) was significantly different between the MAC and RIC arms, respectively. In multivariable analysis for NGS-positive patients, adjusting for disease risk and donor group, RIC was significantly associated with increased relapse (hazard ratio [HR], 6.38; 95% CI, 3.37 to 12.10; P < .001), decreased relapse-free survival (HR, 2.94; 95% CI, 1.84 to 4.69; P < .001), and decreased OS (HR, 1.97; 95% CI, 1.17 to 3.30; P = .01) compared with MAC. Models of AML MRD also showed benefit for MAC over RIC for those who tested positive. CONCLUSION: This study provides evidence that MAC rather than RIC in patients with AML with genomic evidence of MRD before alloHCT can result in improved survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 4×
“In addition, we found a higher rate of TP53 mutations than previously described in newly diagnosed adult patients with AML.17,18,28 TP53 mutations in AML are believed to be associated with resistance to conventional cytotoxic chemotherapy (but possibly not to decitabine21) and are also detectable in the blood after ch…”
BackgroundInfluentialClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Self-citationReduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
Gooley, T. A., Chien, J. W., Pergam, S. A., Hingorani, S., Sorror, M. L., Boeckh, M., Martin, P. J., Sandmaier, B. M., Marr, K. A., Appelbaum, F. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004383 · Cited by 1,493
Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,454
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,303
Self-citationSingle-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
van Galen, P., Hovestadt, V., Wadsworth II, M. H., Hughes, T. K., Griffin, G. K., Battaglia, S., Verga, J. A., Stephansky, J., Pastika, T. J., Lombardi Story, J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.031 · Cited by 1,164
Schuurhuis, G. J., Heuser, M., Freeman, S., Béné, M.-C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-801498 · Cited by 1,041
Self-citationCoombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.010 · Cited by 866
Assessment of Minimal Residual Disease in Standard-Risk AML
Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., Patel, Y., Bhudia, N., Farah, H., Mason, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507471 · Cited by 845
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Jongen-Lavrencic, M., Grob, T., Hanekamp, D., Kavelaars, F. G., al Hinai, A., Zeilemaker, A., Erpelinck-Verschueren, C. A. J., Gradowska, P. L., Meijer, R., Cloos, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716863 · Cited by 786
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 775
Scott, B. L., Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7091 · Cited by 667
Self-citationImmune Escape of Relapsed AML Cells after Allogeneic Transplantation
Christopher, M. J., Petti, A. A., Rettig, M. P., Miller, C. A., Chendamarai, E., Duncavage, E. J., Klco, J. M., Helton, N. M., O’Laughlin, M., Fronick, C. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808777 · Cited by 463
Cord-Blood Transplantation in Patients with Minimal Residual Disease
Milano, F., Gooley, T., Wood, B., Woolfrey, A., Flowers, M. E., Doney, K., Witherspoon, R., Mielcarek, M., Deeg, J. H., Sorror, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602074 · Cited by 443
Araki, D., Wood, B. L., Othus, M., Radich, J. P., Halpern, A. B., Zhou, Y., Mielcarek, M., Estey, E. H., Appelbaum, F. R., & Walter, R. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3826 · Cited by 400
Grimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1533 · Cited by 356
Platzbecker, U., Middeke, J. M., Sockel, K., Herbst, R., Wolf, D., Baldus, C. D., Oelschlägel, U., Mütherig, A., Fransecky, L., Noppeney, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30580-1 · Cited by 345
Klco, J. M., Miller, C. A., Griffith, M., Petti, A., Spencer, D. H., Ketkar-Kulkarni, S., Wartman, L. D., Christopher, M., Lamprecht, T. L., Helton, N. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.9643 · Cited by 339
Thol, F., Gabdoulline, R., Liebich, A., Klement, P., Schiller, J., Kandziora, C., Hambach, L., Stadler, M., Koenecke, C., Flintrop, M., et al. (2018) · Blood · doi:10.1182/blood-2018-02-829911 · Cited by 298
Buckley, S. A., Wood, B. L., Othus, M., Hourigan, C. S., Ustun, C., Linden, M. A., DeFor, T. E., Malagola, M., Anthias, C., Valkova, V., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159343 · Cited by 283
Self-citationBornhäuser, M., Kienast, J., Trenschel, R., Burchert, A., Hegenbart, U., Stadler, M., Baurmann, H., Schäfer-Eckart, K., Holler, E., Kröger, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70349-2 · Cited by 274
Kröger, N., Iacobelli, S., Franke, G.-N., Platzbecker, U., Uddin, R., Hübel, K., Scheid, C., Weber, T., Robin, M., Stelljes, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7349 · Cited by 250
Measurable residual disease testing in acute myeloid leukaemia
Hourigan, C. S., Gale, R. P., Gormley, N. J., Ossenkoppele, G. J., & Walter, R. B. (2017) · Leukemia · doi:10.1038/leu.2017.113 · Cited by 235
Self-citationMinimal residual disease in acute myeloid leukaemia
Hourigan, C. S., & Karp, J. E. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.100 · Cited by 180
Self-citationClonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Cocciardi, S., Dolnik, A., Kapp‐Schwoerer, S., Rücker, F. G., Lux, S., Blätte, T. J., Skambraks, S., Krönke, J., Heidel, F. H., Schnoeder, T. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09745-2 · Cited by 134
Mutation Clearance after Transplantation for Myelodysplastic Syndrome
Duncavage, E. J., Jacoby, M. A., Chang, G. S., Miller, C. A., Edwin, N. C., Shao, J., Elliott, K., Robinson, J., Abel, H., Fulton, R. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804714 · Cited by 129
Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
Hasserjian, R. P., Steensma, D. P., Graubert, T. A., & Ebert, B. L. (2020) · Blood · doi:10.1182/blood.2019004770 · Cited by 122
Kim, T., Moon, J. H., Ahn, J., Kim, Y., Lee, S.-S., Ahn, S., Jung, S., Yang, D., Lee, J., Choi, S. H., et al. (2018) · Blood · doi:10.1182/blood-2018-04-848028 · Cited by 114
Eapen, M., Brazauskas, R., Hemmer, M., Pérez, W. S., Steinert, P., Horowitz, M. M., & Deeg, H. J. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018021980 · Cited by 81
Self-citationSequencing-based measurable residual disease testing in acute myeloid leukemia
Yoest, J. M., Shirai, C. L., & Duncavage, E. J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00249 · Cited by 48
Dillon, L. W., Hayati, S., Roloff, G. W., Tunc, I., Pirooznia, M., Mitrofanova, A., & Hourigan, C. S. (2018) · Haematologica · doi:10.3324/haematol.2018.203133 · Cited by 44
Self-citationGhannam, J. Y., Xu, X., Maric, I., Dillon, L., Li, Y., Hsieh, M., Hourigan, C. S., & Fitzhugh, C. D. (2020) · Blood · doi:10.1182/blood.2019004001 · Cited by 8
Self-citation
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Heuser, M., Freeman, S. D., Ossenkoppele, G. J., Buccisano, F., Hourigan, C. S., Ngai, L. L., Tettero, J. M., Bachas, C., Baer, C., Béné, M.-C., et al. (2021) · Blood · doi:10.1182/blood.2021013626 · Cited by 763
Self-citationDiNardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00108-3 · Cited by 437
Short, N. J., Zhou, S., Fu, C., Berry, D. A., Walter, R. B., Freeman, S. D., Hourigan, C. S., Huang, X., Nogueras Gonzalez, G., Hwang, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4600 · Cited by 390
Self-citation
Metadata
- Authors
- Hourigan, C. S., Dillon, L. W., Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., Deeg, H. J., Devine, S. M., Fernandez, H. F., Giralt, S., Hamadani, M., Howard, A., Maziarz, R. T., Porter, D. L., Scott, B. L., Warlick, E. D., Pasquini, M. C., & Horwitz, M. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-04-20
- Volume
- 38
- Issue
- 12
- Pages
- 1273-1283
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2996657019
- Cited by
- 442
- References
- 39
- FWCI
- 29.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.